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Systemic CD4 immunity: A powerful
clinical biomarker for PD-L1/PD-1
immunotherapy
Miren Zuazo1, Hugo Arasanz1,2, Ana Bocanegra1, Luisa Chocarro1, Ruth Vera2,† , David Escors1,*,†,
Hiroshi Kagamu3,**,† & Grazyna Kochan1,***,†
The search for non-invasive systemic
biomarkers of response to PD-L1/PD-1
blockade immunotherapy is currently a
priority in oncoimmunology. In contrast to
classical tumor biomarkers, the identifi-
cation of clinically useful immunological
biomarkers is certainly a challenge, as
anti-cancer immune responses depend on
the coordinated action of many cell types.
Studies on the dynamics of systemic CD8
T-cell populations have provided indica-
tions that such biomarkers may have a
place in clinical practice. However, the
power of CD8 T-cell subsets to discrimi-
nate clinical responses in immunotherapy
has so far proven to be limited. The
systemic evaluation of CD8 T-cell regula-
tors such as myeloid cells and CD4 T cells
may provide the solution. Here we discuss
the value of systemic quantification of
CD4 T-cell subsets for patient selection in
light of the results obtained by Prof.
Kagamu0s and our team. Our studies have
independently demonstrated that the
evaluation of the pre-treatment status of
systemic CD4 immunity is a critical factor
for the clinical outcome of PD-L1/PD-1
blockade therapy with robust predictive
capacities.
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The revolution of PD-L1/PD-1
blockade immunotherapy, but not
for all
It comes as no surprise nowadays that PD-
L1/PD-1 blockade immunotherapy has
changed the treatment paradigm for several
cancer types. Yet, a significant number of
patients are refractory and the reasons
behind this fact seem to be several. Never-
theless, it highlights the urgent necessity for
accurate biomarkers of response for the
identification of patients that will benefit
from PD-L1/PD-1 blockade immunothera-
pies, and those that will progress or develop
hyperprogressive disease. Moreover, the
precise molecular mechanisms by which
T-cell functions are stimulated by PD-L1/PD-
1 inhibitors remain to be fully understood.
Such understanding is also relevant for
designing approaches that increase clinical
efficacy and overcome resistance to
treatment.
Effector CD8 T cells and their value as
biomarkers of response
Tumor-infiltrating CD8 T cells are the obvious
initial “suspect” for a cellular “immuno-
biomarker” in immunotherapy. At the end of
the day, these cells are the effector cytotoxic
agents over cancer cells. However, there is
some existing controversy on whether PD-L1/
PD-1 inhibitors reinvigorate pre-existing TIL
immunity, or act over systemic T-cell immu-
nity by enhancing the expansion of novel T-
cell clonotypes that will subsequently infiltrate
tumors (Scott et al, 2019; Yost et al, 2019).
This may represent a significant difference
regarding biomarkers, because the study of
systemic immune cell populations from blood
samples is marginally invasive, homogeneous
and less costly than tumor sampling. Various
groups have demonstrated a “proliferative
burst” of systemic CD8 PD-1+ T-cell subpopu-
lations after PD-L1/PD-1 blockade in several
cancer types which correlate with clinical
responses (Huang et al, 2017; Kamphorst
et al, 2017; Kim et al, 2019). For example,
Kim et al (2019) quantified PD-1+ CD8+ T-
cell expansion as a fold change in the percent-
age of Ki67+ cells (Ki-67D7/D0 ≥ 2.8) after the
first week of treatment in patients with thymic
epithelial tumors treated with PD-1 inhibitors.
The predictive value of Ki-67D7/D0 ≥ 2.8 was
validated in two independent cohorts of non-
small cell lung cancer (NSCLC) patients. This
is in agreement with a recent elegant study in
melanoma patients showing rearrangements
in the repertoire of peripheral memory cyto-
toxic CD8 T cells in responders to immune
checkpoint blockade (Valpione et al, 2020).
These studies support the quantification of
proliferating peripheral PD-1+ CD8 T-cell
subpopulations as a systemic biomarker of
responses. CD8 T cells in this context can help
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clinicians on decision-making in the early
onset of the treatment, but do not identify
deleterious adverse events such as hyperpro-
gressive disease.
Systemic CD4 T-cell subsets as robust
indicators of the efficacy of PD-L1/
PD-1 blockade immunotherapies
It is a long-standing fact that proficient CD8
anti-tumor responses largely depend on CD4
help. However, this is often underestimated
or at least overlooked by most studies on
PD-L1/PD-1 blockade. CD4 T helper (Th) 1
cells promote the priming of effector and
memory CD8 T cells by different mecha-
nisms and interactions during antigen
presentation/recognition (Borst et al, 2018)
(Fig 1). Prof Kagamu0s and our team
hypothesized that functional systemic CD4
immunity might be required to achieve effi-
cacious CD8 responses in PD-L1/PD-1 block-
ade therapy.
Our studies have independently demon-
strated that the pre-treatment status of
systemic CD4 immunity is a critical factor
for clinical outcomes to PD-L1/PD-1 block-
ade therapy in NSCLC patients. Using dif-
ferent patient cohorts and analytical
techniques, both studies found that equiva-
lent baseline percentages of peripheral
memory CD4 T cells strongly correlated with
clinical benefit (Kagamu et al, 2019; Zuazo
et al, 2019). In our study, we used conven-
tional flow cytometry to quantify the relative
percentages of systemic CD27 CD28low/
central and effector memory CD4 T cells as a
potent discriminator of differential clinical
outcomes (Zuazo et al, 2019). A cut-off
value of > 40% identified objective respon-
ders with an ORR 50%, while patients with
< 40% showed an ORR of 0%, and were
significantly associated with increased risk
to hyperprogressive disease (Arasanz et al,
2020). Patients with low baseline numbers
of memory CD4 T cells showed strong CD4
T-cell dysfunctionality. Moreover, CD8
proliferative responses were only recovered
in patients who had functional CD4
responses before treatment initiation.
Kagamu et al simultaneously obtained simi-
lar conclusions through multiparametric
flow cytometry identifying an equivalent
CD62Llow effector memory CD4 T population
which robustly discriminated patients with
distinct clinical outcome, with similar
threshold values found by us over systemic
memory CD4 T cells. Hence, responders to
PD-1 blockade therapy had significantly
higher baseline proportions of CD62Llow
CD4 T cells, while non-responders also had
increased Tregs systemically. The study by
Kagamu et al (2019) refined an algorithm
that accounted for the ratio between
memory CD4 and Treg cells to discriminate
responders with a cut-off value of ≥192 in
two independent NSCLC cohorts. Gene
expression analysis of CD62Llow CD4 T cells












































Figure 1. The contribution of CD4 Th1 subsets to anti-tumor immunity.
The figure summarizes the well-established roles of CD4 Th1 subsets in anti-tumor responses. Right, CD4 Th1 cells allow the correct priming and differentiation of naive CD8
T into CTLs by secretion of cytokines and co-stimulatory interactions with DCs within the secondary lymphoid organs. This process termed DC licensing leads to DC
maturation by CD40L-CD40 binding. CD40-CD40L signaling on DCs induces production of IL-12 and IL-15 and up-regulates co-stimulatory ligands CD80, CD86, and CD70,
providing the required signals for CD8 CTL priming. CD80, CD86, and CD70 co-stimulatory ligands on activated DC bind to their receptors CD28 and CD27 on naive CD8 T cells
leading to CTL differentiation and survival. CD8 CTLs infiltrate tumors and exert cytotoxic responses against tumor cells after TAA recognition. Th1, T helper 1; CTL, cytotoxic T
lymphocyte; DC, dendritic cell; TAA, tumor-associated antigens.
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engaged proliferating Th1 cells, and up-regu-
lated pathways involved in the promotion of
CD8 CTL responses.
Conclusions and future directions
The future of CD4 T cells as systemic
biomarkers of response to PD-L1/PD-1
blockade lies on more extensive validation
cohorts for distinct cancer types, which is
currently under way. The statistically power-
ful ROC analyses in our independent studies
support its clinical application. In addition,
each study used different phenotypic mark-
ers for the identification of CD4 memory
populations. Therefore, unification of data
provided by both studies will help us select-
ing the CD4 memory subpopulation with the
strongest predictive value. Our working
hypothesis is that CD4 memory help func-
tions directly influence PD-L1/PD-1 efficacy
over anti-tumor CD8 responses. Neverthe-
less, the molecular mechanisms remain to
be fully understood, but will very likely
include antigen-presenting cells such as
dendritic cells. Finally, dynamic changes of
CD4 T populations could help evaluate
responses in “real-time” from small blood
samples during the duration of treatments.
This will surely help identifying patients
with a high risk of developing hyperprogres-
sion (Kagamu et al, 2019; Arasanz et al,
2020).
Concluding, strategies to restore CD4
immunity in patients before starting PD-L1/
PD-1 blockade therapies could be part of the
solution to minimize refractoriness.
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